Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe disease show hyperactivation of the immune system, which can affect multiple organs besides the lungs. Here, we propose that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels. Microthrombotic complications may contribute to acute respiratory distress syndrome (ARDS) and other organ dysfunctions. Therapeutic strategies aimed at reducing immunothrombosis may therefore be useful. Several antithrombotic and immunomodulating drugs have been proposed as candidates to treat patients with SARS-CoV-2 infection. The growing understanding of SARS-CoV-2 infection pathogenesis and how it contributes to critical illness and its complications may help to improve risk stratification and develop targeted therapies to reduce the acute and long-term consequences of this disease.

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 / Bonaventura, A.; Vecchie, A.; Dagna, L.; Martinod, K.; Dixon, D. L.; Van Tassell, B. W.; Dentali, F.; Montecucco, F.; Massberg, S.; Levi, M.; Abbate, A.. - In: NATURE REVIEWS IMMUNOLOGY. - ISSN 1474-1733. - 21:5(2021), pp. 319-329. [10.1038/s41577-021-00536-9]

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

Dagna L.;
2021-01-01

Abstract

Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe disease show hyperactivation of the immune system, which can affect multiple organs besides the lungs. Here, we propose that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels. Microthrombotic complications may contribute to acute respiratory distress syndrome (ARDS) and other organ dysfunctions. Therapeutic strategies aimed at reducing immunothrombosis may therefore be useful. Several antithrombotic and immunomodulating drugs have been proposed as candidates to treat patients with SARS-CoV-2 infection. The growing understanding of SARS-CoV-2 infection pathogenesis and how it contributes to critical illness and its complications may help to improve risk stratification and develop targeted therapies to reduce the acute and long-term consequences of this disease.
2021
Coagulation system,Antimicrobial responses,Cytokines,Innate immunity,Viral infection
File in questo prodotto:
File Dimensione Formato  
s41577-021-00536-9.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 1.88 MB
Formato Adobe PDF
1.88 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/135907
Citazioni
  • ???jsp.display-item.citation.pmc??? 428
  • Scopus 575
  • ???jsp.display-item.citation.isi??? 509
social impact